|
Market Closed -
Nasdaq Helsinki
12:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 79.00 EUR | -0.25% |
|
-1.80% | +24.12% |
| 08-27 | Orion launches share buyback for incentive program | FW |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 12.94B | |||||
| 1,002B | |||||
| 644B | - | ||||
| 443B | |||||
| 343B | |||||
| 262B |
- Stock Market
- Stocks
- ORNBV Stock
- Charts Orion Oyj
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
